// App-Quantinova.ai

POS1039 (2022) : DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS: ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND ITS COMPONENTS

Researchers

Presenter

  • A. Kavanaugh

Principal Investigators

  • L. Coates

  • J. F. Merola

  • P. J. Mease

  • M. Nowak

  • S. Banerjee

  • L. Hippeli

  • T. Lehman

Medical Centers

  • University of California, San Diego, Rheumatology, La Jolla, United States of America

  • University of Oxford, Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

  • Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, United States of America

  • 2Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, Washington, United States of America

  • Bristol Myers Squibb, Rheumatology and Dermatology, Princeton, United States of America

  • Bristol Myers Squibb, Medical Immunology, Princeton, United States of America

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

  • Inflammatory Arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03881059

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved